---
title: "CraniUS Therapeutics secures $20M in Series B funding for NeuroPASS™ platform development to penetrate blood-brain barrier."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/273994663.md"
description: "CraniUS Therapeutics LLC, a private neurotechnology company, recently disclosed that it has secured $20 million in Series B funding. This substantial amount is intended to expedite the advancement of NeuroPASS™, a groundbreaking project designed to enable direct therapeutic access beyond the blood-brain barrier."
datetime: "2026-01-28T12:52:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/273994663.md)
  - [en](https://longbridge.com/en/news/273994663.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/273994663.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/273994663.md) | [繁體中文](https://longbridge.com/zh-HK/news/273994663.md)


# CraniUS Therapeutics secures $20M in Series B funding for NeuroPASS™ platform development to penetrate blood-brain barrier.

CraniUS Therapeutics LLC, a private neurotechnology company, recently disclosed that it has secured $20 million in Series B funding. This substantial amount is intended to expedite the advancement of NeuroPASS™, a groundbreaking project designed to enable direct therapeutic access beyond the blood-brain barrier.

### Related Stocks

- [Fulcrum Therapeutics, Inc. (FULC.US)](https://longbridge.com/en/quote/FULC.US.md)
- [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [iShares Global Healthcare ETF (IXJ.US)](https://longbridge.com/en/quote/IXJ.US.md)
- [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [CNS Pharmaceuticals, Inc. (CNSP.US)](https://longbridge.com/en/quote/CNSP.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)

## Related News & Research

- [Craig-Hallum Sticks to Their Buy Rating for Apogee Therapeutics (APGE)](https://longbridge.com/en/news/277492684.md)
- [BUZZ-Erasca rises on partnership with Tango to test new cancer drug combo](https://longbridge.com/en/news/277972424.md)
- [Arcutis Biotherapeutics Spotlights ZORYVE Surge, 2025 Revenue Beat and Key FDA Milestones at TD Cowen](https://longbridge.com/en/news/277784572.md)
- [Amylyx Pharmaceuticals Says 2026 Could Be “Transformative” Ahead of Avexitide Phase 3 Readout](https://longbridge.com/en/news/277751027.md)
- [BUZZ-MAIA Biotechnology plunges after $30 million share sale](https://longbridge.com/en/news/277605454.md)